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The epidemic of heart failure has stimulated interest
in understanding cardiac regeneration. Evidence
has been reported supporting regeneration via
transplantation of multiple cell types, as well as
replication of postmitotic cardiomyocytes. In addi-
tion, the adult myocardium harbors endogenous
c-kitpos cardiac stem cells (eCSCs), whose relevance
for regeneration is controversial. Here, using dif-
ferent rodent models of diffuse myocardial damage
causing acute heart failure, we show that eCSCs
restore cardiac function by regenerating lost cardio-
myocytes. Ablation of the eCSC abolishes regene-
ration and functional recovery. The regenerative
process is completely restored by replacing the
ablated eCSCs with the progeny of one eCSC.
eCSCs recovered from the host and recloned retain
their regenerative potential in vivo and in vitro. After
regeneration, selective suicide of these exogenous
CSCs and their progeny abolishes regeneration,
severely impairing ventricular performance. These
data show that c-kitpos eCSCs are necessary and
sufficient for the regeneration and repair of myocar-
dial damage.INTRODUCTION
Most mammalian adult tissues harbor a subpopulation of tissue-
specific stem and progenitor cells (hereafter referred together as
stem cells) that differentiate into some or all of the parenchymal
cells of their tissue of origin (Weissman, 2000). Cardiac resident
stem cells in embryonic, neonatal, and adult mammalian heart
have been identified by different membrane markers (c-kit,
Sca-1, Abcg-2, Flk-1, and PDGFR-a) and transcription factors
(Isl-1, Nkx2.5, GATA4, and Wt-1) (Vincent and Buckingham,
2010; Torella et al., 2007; Chong et al., 2011; Smart et al.,
2011). It is likely that a number of these identified cell populations
represent different developmental and/or physiological stages
of a unique resident stem cell (Ellison et al., 2010).
Intensive research on the adult mammalian heart’s capacity
for self-renewal has led to a consensus that new cardiomyocytes
(hereinafter CMs) are indeed formed throughout adult mam-
malian life (Hsieh et al., 2007; Bergmann et al., 2009). However,
the physiological significance of this renewal, the origin of the
new CMs, and the rate of adult CM turnover are still highly
debated. Whereas some recent studies have calculated a yearly
CM turnover of about 1% (Bergmann et al., 2009), others have
calculated 4%–10% (Senyo et al., 2013) and some as high as
40% per year (Kajstura et al., 2012). Similar discrepancy exists
regarding the origin of the new CMs and their physiological sig-
nificance. Myocyte replacement, particularly after injury, was
originally attributed to differentiation of a stem cell compartmentCell 154, 827–842, August 15, 2013 ª2013 Elsevier Inc. 827
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(Beltrami et al., 2003), a source confirmed by genetic cell fate
mapping (Hsieh et al., 2007). More recently, it has been reported
that CMs in the border zone of an infarct are replaced by the di-
vision of pre-existing postmitotic myocytes (Senyo et al., 2013).
These results would shift the target of regenerative therapy
toward boosting mature CM cell-cycle re-entry. However, the
experiments of Senyo et al. (2013) document that a very small
fraction of CM DNA replication occurs in cells that have already
activated the myosin heavy chain (MHC) gene, a well-known
aspect of myocyte development; these data fall short of docu-
menting mature myocyte re-entry into the cell cycle.
The adult endogenous c-kitposCD45negtryptaseneg cardiac
stem cells (hereafter, c-kitposeCSCs or just eCSCs) participate
in adaptations to myocardial stress (Ellison et al., 2007a; Waring
et al., 2012), and, when transplanted into the myocardium,
regenerate most cardiomyocytes and microvasculature lost in
an infarct (Beltrami et al., 2003). Recently, the in situ myogenic
potential of adult c-kitpos cardiac cells has been questioned as
being significantly reduced, particularly in comparison to their
neonatal counterparts (Zaruba et al., 2010; Jesty et al., 2012).
To revisit the regenerative potential of c-kitpos eCSCs, we
employed experimental protocols of severe diffuse myocardial
damage which, unlike an experimental infarct, spares the eCSCs
(Ellison et al., 2007b), in combination with several genetic murine
models and cell transplantation approaches. Here, we demon-
strated that eCSCs are necessary and sufficient for myocyte
regeneration, leading to complete cellular, anatomical, and func-
tional myocardial recovery.
RESULTS
Robust eCSC Activation and Myocyte Regeneration
Follow Myocardial Damage in the Presence
of a Patent Coronary Circulation
To follow c-kitposeCSC physiological response to cardiac injury,
we induced severe diffuse myocardial damage in adult rats with
a single high dose of isoproterenol (ISO) (Ellison et al., 2007b).
New cell formation was monitored with bromodeoxyuridine
(BrdU) labeling in vivo (Waring et al., 2012). In the presence of
a patent coronary circulation, ISO produces a Takotsubo-like
cardiomyopathy (Akashi et al., 2008) with both diffuse subendo-
cardial and apical CM death. This acute insult kills 8%–10% of
the left ventricle (LV) CMs and results in overt acute heart failure
(Ellison et al., 2007b). Interestingly, the myocardial damage
and heart failure spontaneously reverse anatomically and func-
tionally by 28 days (Figure S1 available online). Whereas in theFigure 1. eCSC Activation and Myogenic Differentiation following Diffu
(A–C) c-kitposeCSCs in myocardium (A), FACS cell-cycle analysis (B), and perce
versus CTRL.
(D and E) Confocal microscopy (D) and quantification of c-kitpos/Nkx2.5pos pro
Scale bar, 20 mm. *p < 0.01 versus CTRL.
(F–I) Confocal microscopy (F and G) and quantification (H and I) of small newly form
BrdU was injected (i.p.) twice daily. Scale bar, 50 mm (F) and 20 mm (G). *p < 0.0
(J) Confocal microscopy of a small BrdUpos CM (arrow) with gap junction format
Scale bar, 20 mm.
(K) Rod-shaped BrdUpos ventricular CMs isolated 28 days after ISO (n = 4). Scal
(L) BrdUpos CM diameter. *p < 0.05 versus CTRL BrdUneg; yp < 0.05 versus CTR
All data are mean ± SD. See also Figure S1.normal myocardium (CTRL) most c-kitposeCSCs are quiescent
(>90% BrdUneg and Ki67neg), after ISO damage, a high fraction
enters the cell cycle (Figures 1A–1C and S1). At day 3, 88%
are BrdUpos (Figure 1C), leading to an 8-fold increase in
eCSC number, which decreases thereafter but remains above
CTRL for up to 28 days (Figure 1A).
The expansion of the eCSC pool in response to CM loss by ISO
damage was followed by their commitment to myocardial cell
lineages. Indeed, many of the c-kitpos eCSCs expressed GATA4
(FigureS1) andNkx2.5 (Figures 1Dand 1E), two early transcription
factors of the cardiac lineage which, together with Tbx5 and
MEF-2C, are essential for the differentiation of mesoderm and re-
programming of fibroblasts into the CM lineage (Takeuchi and
Bruneau, 2009; Qian et al., 2012; Song et al., 2012). The number
of c-kitposNkx2.5posGATA4pos cells increased 4-fold over CTRL
by day 3 (Figures 1E and S1). This sequential transition from un-
differentiated cells to committed progeny is further illustrated by
the transcription of sarcomeric and gap junction genes (troponin
I,cTnI; connexin 43,Cnx43) and the presenceof their correspond-
ing proteins, even though at lower levels than found in the adult
spared CMs (Figures 1D and S1). These new c-kitposGATA-4pos-
Nkx2.5pos myogenic progenitors express b-MHC, the isoform
characteristic of the fetal rat heart (Lompre´ etal., 1984).Noexpres-
sion of the a-Mhc gene, characteristic of adult rat CMs and ex-
pressed by spared CMs 72 hr after ISO, was detected (Figure S1).
Starting at day 3 post-ISO, very small mononucleated
BrdUposKi67pos CMs, including some in mitosis, were detected
(Figures 1F–1L), which is indicative of immature, proliferative
CMs. These new CMs were localized mainly in the LV subendo-
cardium and apex, the area most severely damaged by ISO.
From 3 to 28 days, there was a significant increase in the number
(Figures 1H and 1I) and size of these CMs, which were nearly all
mononucleated and smaller than the spared (BrdUneg) ones (Fig-
ure 1L). The BrdUpos CMs also expressed CNX43, suggestive of
gap junction formation and integration with the neighboring
myocardium (Figure 1J). Rod-shaped small BrdUpos CMs were
also detected as single cells when isolated from ISO-treated
hearts (Figure 1K). Their smaller size indicates that, despite the
normal histology and function of the ISO-treated hearts 4 weeks
postinjury, the newly regenerated CMs had not yet fully matured.
Myocyte Regeneration after DiffuseMyocardial Damage
Is Not the Product of Pre-existing Myocyte Division
or Bone Marrow Cells
BrdU labeling and Ki67 expression cannot establish whether the
new CMs are generated by the reported division of pre-existingse Myocardial Damage
ntage of activated c-kitposBrdUposeCSCs (C) in CTRL and after ISO. *p < 0.01
genitors (E; arrows) and myogenic precursor (arrowhead) 3 days after ISO.
ed (BrdU) mitotic and proliferating (Ki67) CMs 28 days after ISO. 50mg kg1 of
5 versus CTRL.
ion (Cnx43, white; arrowheads) between neighboring CMs 28 days after ISO.
e bar, 50 mm.
L BrdUpos.
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Figure 2. Myocyte Regeneration after Diffuse Myocardial Damage
(A) Schematic of pulse-chase genetic labeling of CM renewal.
(B) Representative immunostaining with antibodies against GFP and b-gal (both brown-DAB staining) in the subendocardial, apical layer of CTRL 28 days after
ISO. Scale bar, 50 mm.
(C) Fraction of GFPpos and b-galpos CMs in CTRL and after ISO. *p < 0.05 versus CTRL.
(legend continued on next page)
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adult CMs or by the activation and ensuing differentiation of a
stem cell compartment. To specifically address this issue, we
traced the cell lineage of the new CMs. We generated double-
transgenic mice (MerCreMer-ZEG) (Hsieh et al., 2007; Loffredo
et al., 2011) in which, upon tamoxifen administration, b-galacto-
sidase (b-gal) is replaced by enhanced GFP exclusively in
cardiac cells that have already activated the Myh6 gene (and,
therefore, the transgene carrying the cre recombinase gene),
which are either postmitotic CMs or amplifying cells already
committed to the CM lineage (i.e., immature myocytes/myocyte
precursors).
In tamoxifen-naive MerCreMer-ZEG mice, 99 ± 0.2% of the
CMs express b-gal and are negative for GFP (the leakage of the
Myh6-Cre construct in these animals is 0.2%). Tamoxifen
correctly switched b-gal to GFP in CMs (Figures 2A–2C). This
resulted in hearts composed of 83 ± 3% GFPpos and 17 ± 2%
b-galpos CMs (Figures 2B and 2C), as previously reported (Hsieh
et al., 2007; Senyo et al., 2013). In this setting, if new CMs
(BrdUpos) originated from division of pre-existing CMs, they
should be mostly GFPpos, and the ratio between GFPpos and
b-galpos CMs should remain unchanged at 80/20. If instead
the new CMs originate from non-CM cells, they should be
b-galpos and produce a ‘‘dilution’’ of GFPpos CMswith a decrease
of the GFPpos/b-galpos CM ratio (Figure 2A).
In mice, ISO injection caused the same type of myocardial
damage and LV dysfunction shown in rats, resulting in c-kitpos
eCSC activation, CM regeneration, and recovery of cardiac func-
tion (Figure S2). When ISO was administered to CM-recombined
MerCreMer/ZEG mice (Figure 2A) followed by BrdU labeling,
28 days later there was a significant increase in the percentage
of b-galpos CMs: 18% ± 2.5% in saline-treated mice versus
26.5 ± 2% in ISO-injured mice (Figures 2B and 2C), accompa-
nied by a decrease of GFPpos CMs in the hearts of ISO-treated
mice (73.5 ± 3.5%) compared to CTRLmice (82 ± 3.5%) (Figures
2B and 2C). There was also a concomitant increase of BrdUpos
CMs (9 ± 2%) in the ISO-treated hearts, and these were b-galpos
(Figures 2D and 2E). These numbers match the CM loss pro-
duced by ISO administration (Figure S2). In contrast, we de-
tected very few newly generated BrdUposb-galpos CMs (0.15 ±
0.05%) in saline-treated CTRL mice (Figure 2E). This result
concurs with Hsieh et al. (2007) but disagrees with the interpre-
tation of Senyo et al. (2013) using the same genetic tools. This
discrepancy might be due to the different injury models used.
In contrast to coronary ligation, ISO kills a large number of
CMs in the presence of patent coronary circulation, and it spares
the eCSCs. Thus, ISO provides a more physiologic test for the
endogenous reparative potential of the adult heart (Ellison
et al., 2007b). Furthermore, during the 2 week administration of
tamoxifen for Cre induction, it would be expected that some
eCSCs have committed to the myogenic lineage and activated(D and E) Confocal microscopy (D) and percentage (E) of newly formed b-galpos/
(F) Immunocytochemistry identifies a small BrdUpos/YFPneg mononucleated ro
after ISO.
(G) Flow cytometric analysis of GFP within the c-kitpos/CD45neg eCSC compartm
(H) Confocal microscopy of newly formed BrdUpos/GFPneg CMs.
(I) CM regeneration after BMGFP transplantation. *p < 0.05 versus CTRL.
All data are mean ± SD. See also Figure S2.theMyh6 gene with recombination of the transgene and genera-
tion of b-galpos CMs, as reported by Dong et al. (2012).
Although cell fusion might allow the expression of both GFP
and b-gal in the same CM, it can be ruled out because the per-
centage of CMs positive for both markers was negligible
(<0.1%) in saline-treated CTRL and ISO-injured mice. The possi-
bility that the decrease in GFPpos and corresponding increase in
b-galpos CMs after ISO might be due to a higher susceptibility of
GFP-labeled CMs to ISO damage was also excluded by the
fact that the percentage of necrotic and apoptotic GFPpos and
b-galpos CMs 1 day after ISO was similar (Figure S2).
Finally, we dissociated to single cells CMs from the hearts of
double-transgenic MerCreMer:RYP mice obtained by crossing
MerCreMer with R26R-EYFP (RYP) mice (Qian et al., 2012), in
which the CMs were labeled with the enhanced yellow fluores-
cent protein (EYFP) upon tamoxifen injection. In agreement
with the data shown on MerCreMer:ZEG mice, tamoxifen-driven
induction of YFP marked 80% of endogenous CMs in the
uninjured CTRL heart, which decreased to 72% in the apex
(and subendocardium) of injured hearts at 28 days after ISO.
Only the YFPneg fraction isolated from the CM-recombined
double-transgenic mice was BrdUpos (Figure 2F). Most of these
newly generated BrdUposYFPneg CMs were rod shaped, mono-
nucleated, and smaller than the pre-existing (mostly binucleated)
YFPposBrdUneg CMs (Figure 2F).
In conclusion, after diffuse myocardial injury, new CMs are not
generated (at least in quantities above background) through the
division of pre-existing terminally differentiated CMs as claimed
(Senyo et al., 2013) but rather are generated from non-CM cells
with the characteristics of a stem compartment (Hsieh et al.,
2007).
Bone marrow (BM)-derived cells have been implicated in car-
diac regeneration after myocardial infarction (Orlic et al., 2001;
Loffredo et al., 2011). To test this possibility, either saline or
ISO was injected to sublethally g-irradiated mice 3 months
after successful reconstitution of their BM with BM cells from
TgGFP mice (Sata et al., 2002). In both CTRL and ISO-treated
animals, a small fraction (3.5 ± 2% versus 5 ± 2%, respectively)
of c-kitposCD45neg cardiac cells was GFP positive at 28 days
(Figure 2G). However, despite extensive histological analysis
and CM isolation, we were unable to find a single BM-derived
GFPposBrdUpos or GFPpos CM in either ISO-treated or CTRL
hearts (Figures 2H and 2I). Therefore, BM-derived cells do not
directly contribute in any significant manner to new CM forma-
tion in normal or ISO-damaged hearts.
New Myocytes after Diffuse Myocardial Injury Originate
from Resident c-kitposeCSCs
To determine whether c-kitposeCSCs replenish the CMs lost
by diffuse myocardial damage, we genetically tagged in situ aBrdUpos CMs 28 days after ISO. Scale bar, 20 mm. *p < 0.05 versus CTRL.
d-shaped CM, isolated from pulse-labeled MerCreMer:RYP mice, 28 days
ent, following BMGFP transplantation and 28 days after ISO. n = 5.
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Figure 3. Myocyte Replenishment by c-kitpos eCSCs following Diffuse Myocardial Damage
(A) Schematic of pulse-chase genetic labeling approach of resident c-kitposeCSCs and their progeny in situ.
(B and C) Flow cytometric analysis shows c-kit/cre lentivirus labeling of eCSCs and CMs in vivo.
(D) Representative confocal microscopy of apical YFP-labeled c-kitposeCSCs (c-kit/YFP, green/white arrowheads; c-kitpos eCSCs not transfected, green
arrowheads). Scale bar, 20 mm.
(E) Percentage of BrdUpos CMs and those that were YFPpos in the LV and apex 28 days after ISO. Data are mean ± SD. *p < 0.05 versus CTRL or LV.
(F) Representative confocal microscopy of apical c-kitposeCSC-derived YFPposBrdUpos CMs 28 days after ISO. Scale bar, 20 mm.
(G and H) Representative immunocytochemistry of BrdUpos/YFPpos and BrdUpos/YFPneg isolated CMs (G) and flow cytometric analysis of YFP/cTnIpos CMs (H)
isolated from lenti c-kit/cre mice 28 days after ISO or saline (CTRL). n = 3.
(legend continued on next page)
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subset of adult resident c-kitposeCSCs and their myocyte
committed progeny (Figure 3A). We generated a lentivirus
carrying Cre-recombinase under the control of the c-kit pro-
moter (Lenti-c-kit/Cre) with a pattern of expression restricted
to c-kitpos cells (Figure S3; Cairns et al., 2003). To confine lenti-
virus release to the LV myocardium, we employed a fibrin-based
PEGylated hydrogel for epicardial delivery (Zhang et al., 2006).
To increase delivery, we also injected the lentivirus directly
into the apex, the region with the greatest CM damage after
ISO (Ellison et al., 2007b) and with the highest concentration of
c-kitpos eCSCs (Ellison et al., 2011). This combined strategy
was used to selectively release Lenti-c-kit/Cre into the myocar-
dium of RYP reporter mice (Figure 3A). In these mice, the uptake
of the c-kit/Cre recombinase lentivirus by any c-kitpos cell deletes
the STOP sequence in the transgene and switches on the
expression of EYFP. After 2 weeks, peripheral blood cells and
BM-derived cells were reproducibly negative for EYFP (Fig-
ure S3). Importantly, 38 ± 5% of total and 65 ± 7% of apex-
confined c-kitposeCSCs were EYFP positive (Figures 3B–3D).
Lenti-c-kit/Cre injection induced EYFP expression exclusively
in cardiac c-kitpos cells, whereas CMs (Figure 3C) and other
c-kitneg myocardial cell types were all negative for EYFP (Fig-
ure S3). When the recombined EYFPposc-kitposCD45negeCSCs
were isolated from the hearts of RYP mice at 2 weeks after
lentivirus release, they were phenotypically indistinguishable
from the unrecombined EYFPneg-c-kitposCD45negeCSCs and
exhibited the typical properties of resident eCSCs, being clono-
genic, self-renewing, and multipotent (Figure S3).
14 days after local release of the Lenti-c-kit/Cre, RYP mice
received either ISO or saline (CTRL) injection. 28 days after
ISO, we confirmed that there were no recombined EYFP-positive
cells in the c-kitpos-enriched fraction of the nucleated cells of
peripheral blood or within the BM from CTRL and ISO-injured
mice (Figure S3). In CTRL mice, after 4 weeks of BrdU in vivo
labeling, a total of 0.18 ± 0.07% BrdUpos CMs was detected,
and only a fraction of those newly generated cells were c-kitpos
eCSC-derived EYFPposBrdUpos CMs (0.06 ± 0.02%/total CMs)
(Figure 3E). In the ISO-treated hearts, a significant fraction of
a total 9.5 ± 2% of newly formed CMs were EYFP positive
(43 ± 3% of total BrdUpos CMs, which, in the apex, reached
74 ± 7%) (Figures 3E and 3F), indicating that these newly gener-
ated CMs are the progeny of the c-kitposeCSCs. We confirmed
the identity of both YFPpos- and YFPneg-BrdUpos CMs in isolated
CMs 28 days after ISO (Figure 3G) by fluorescence-activated cell
sorting (FACS). YFP expression was analyzed in unfixed CMs
to avoid fluorescent protein leakage, as well as fixative-induced
autofluorescence. FACS detected >98% cTnI-positive cells in
the fixed aliquot of the CM preparation in both CTRL and ISO
groups (Figure 3H). <0.5% of YFPpos cells were detected in the
unfixed aliquot of the same CM preparation from CTRL c-kit/
Cre recombined RYP mice (Figure 3H). Thus, it was technically
impossible to ascertain by FACS whether they were truly c-kitpos(I) Heatmap showing two-way hierarchical cluster of the expression of 3,774 gene
Enriched Gene Ontology (GO) terms for the genes of each cluster are shown to
(J) Heatmap showing expression pattern of CM and cell-cycle-specific genes i
for each.
See also Figures S3 and S4 and Table S1.eCSC-derived CMs. More significantly, YFPpos cells were clearly
recognized within the unfixed CM preparation from ISO-injured
hearts (2.9 ± 0.5% in total LV and 8.3 ± 1% in LV apex) (Fig-
ure 3H). We further verified that the YFP signal truly originated
from YFPpos CMs by sorting the total CM preparation and
demonstrating that R99% were aSA positive after cell fixation
(Figure S4). These results were not due to c-kit re-expression
in adult CMs, as suggested previously in cryo-injured hearts
(Tallini et al., 2009). The absence of such re-expression in saline-
or ISO-treated transgenic mice expressing GFP under the c-kit
promoter (Figure S4) rules out this potential confounding factor.
To further test the identity and the degree of differentiation of
the newly regenerated eCSC-derived CMs, we obtained global
gene expression profiles by microarray of c-kitpos eCSCs,
c-kitpos eCSC-derived YFPpos CMs, and normal adult CMs.
The c-kitpos eCSC-derived YFPpos CMs were obtained by FACS
sorting from Lenti-c-kit/cre recombined RYP mice 28 days after
ISO injury (Figure S4). These CMs had a gene expression profile
that closely resembled the profile of adult CMs (Figures 3I and
3J). Comparison of c-kitposeCSCs versus c-kitposCSC-derived
YFPpos CMs versus adult mature CMs reveals a clear transcrip-
tome shift going from uncommitted c-kitposCSCs to CM-lineage
commitment, followed by immature to mature CMs (Figures 3I
and 3J and Table S1). The eCSC-derived YFPpos CMs expressed
the main CM transcription factors, as well as sarcomeric con-
tractile genes, but still maintained the expression of cell-cycle-
related and high-metabolic-state genes typical of immature
(neonatal) not yet terminally differentiated CMs (Figures 3I and
3J). Intriguingly, even after having acquired mature sarcomeric
structures and a rod shape (Figure 3G), eCSC-derived YFPpos
CMs show an incomplete switch from retinoblastoma-like 1
(Rbl-1 or p107) to retinoblastoma protein (Rb), which is a
requirement for permanent CM withdrawal from the cell cycle
(Schneider et al., 1994). These data further demonstrate that
resident c-kitposeCSCs generate new CMs in vivo that are still
immature 4 weeks after their birth.
Taken together, these in vivo genetic cell-fate-mapping ex-
periments show that c-kitposeCSCs have intrinsic cardiac
regenerative potential, replacing lost CMs lost after diffuse
myocardial injury.
c-kitposeCSCs Have Strong Tropism for the Damaged
Myocardium
To determine whether the ISO-injured myocardium provides
a homing milieu for c-kitposeCSCs, 5 3 105 cells derived from
a single eCSC GFP-tagged clone (eCSCsGFP) (Figure 4A) were
injected through the tail vein of rats 12 hr after ISO injury. As
cell control, ISO-injured rats were injected with 5 3 105 GFP-
tagged c-kit negative sorted CM-depleted cardiac cells (c-kit-
negMDCCsGFP; containing 86 ± 5% cardiac fibroblasts, 13 ±
3% vascular smooth muscle, 1 ± 1% endothelial and <0.001%
c-kitpos cardiac cells). To control for the role of injury in thes that underwent a log fold changeR 1 or%1 (p < 0.005). See also Table S1.
the right.
n c-kitposeCSCs, YFPpos CMs, and adult terminally differentiated CMs. n = 3
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Figure 4. c-kitposCSCs Exhibit Selective Homing to ISO-Damaged Myocardium and Differentiate into New CMs
(A) Immunocytochemistry of clonal c-kitposCSCsGFP. Scale bar, 50 mm.
(B)Quantificationof tail-vein-injectedc-kitnegMDCCsGFPandc-kitposCSCsGFP in thesubendocardial layerafter ISO. *p<0.001versusCTRLandc-kitnegMDCCsGFP.
(C–F) Confocal microscopy representative images of GFPpos c-kitnegMDCCs (C) and c-kitposCSCGFP in the myocardium of CTRL (D) and at 1 (E) and 6 (F) days
after ISO and tail-vein injection. Scale bar, 30 mm.
(legend continued on next page)
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homing, both cell preparations were also administered to unin-
jured, saline-treated (CTRL) animals.
At all time points, the myocardium of CTRL and ISO animals
transplanted with c-kitnegMDCCsGFP had on average <1 GFPpos
cell/105 nuclei (Figures 4B and 4C). In the CTRL hearts trans-
planted with CSCsGFP, there were 81 ± 31 CSCsGFP/105 nuclei
at 24 hr after injection (Figures 4B and 4D and Table S2). In con-
trast, in ISO-injured hearts, there was very efficient cardiac
homing and engrafting of the transplanted CSCsGFP, which
accounted for most of the injected cells (Figures 4B, 4E, and
4F) (Table S2). The high cardiac tropism and engrafting efficiency
of the cloned CSCsGFP compared to the extra-cardiac tissues is
shown in Table S2 and Figure S5. Of the myocardial-homed
CSCsGFP, 55 ± 5%, 20 ± 4%, and 8 ± 3% were Ki67pos at 1, 6,
and 28 days posttransplantation, respectively (Figure 4G). There
was also an increase in GFPpos cells expressing a-sarcomeric
actin at 6 (25 ± 3%) and 28 (42 ± 3%) days. At 28 days,
CSCGFP-derived newly formed GFPpos CMs (4 ± 1%; Figure 4H)
had well-developed sarcomeres and were larger and more
differentiated (diameter of 10 ± 2mm) but were still smaller than
normal adult fully differentiated GFPneg CMs (diameter of 14 ±
1mm; p < 0.01 versus GFPpos CMs). We further quantified the
number of transplanted c-kitposCSC-derived GFPpos CMs by
FACS, which was in agreement with the immunohistochemistry
data (Figure S5). At 28 days after ISO and CSCGFP tail-vein injec-
tion, of the total GFPpos cardiac cells, the majority became CMs
(64 ± 4%) but also became smooth muscle (10 ± 3%) and endo-
thelial (14 ± 3%) vascular cells and fibroblasts, whereas few of
them stayed as c-kitposCSCs (Table S3).
To further ascertain that the tail-vein-injected cells generated
bona fide CMs, c-kitposeCSCs expressing GFP under the control
of the cardiac troponin I (cTnI) promoter were tail injected
after ISO as above. At 28 days, a population of CSC-derived
cTnIposGFPpos CMs was detected (Figure S5).
Because the SDF-1-CXCR4 axis is involved in retention and
mobilization of stem cells in the adult (Askari et al., 2003), we
evaluated whether this receptor-ligand pair homes CSCsGFP to
ISO-injured myocardium. SDF-1 is rapidly upregulated in CMs
after ISO damage (Figures 4I and S5). 5 3105-c-kitposeCSCs
genetically modified to knock down expression of the SDF-1 re-
ceptor with a lentiviral vector carrying a CXCR4 shRNA tagged
with GFP (CXCR4KDCSCsGFP; Figure S5) were tail-vein injected
into rats 12 hr after ISO injury. The CXCR4KDCSCsGFP did not
show any cardiac tropism, as most were lodged in the spleen
and lungs (Figure 4J and Table S4). Concurrently, tail-vein-
injected CSCsGFP also failed to home to the myocardium of
ISO-injured rats treated with an anti-SDF-1 neutralizing antibody
20 min before and 12 hr after cell injection (Figure 4K).
These results show that thec-kitposCSCshaveastrong tropism
for the damaged myocardium, which is CXCR4-SDF-1 depen-
dent and is where the enhanced expression of SDF-1 by the
surviving myocardium serves as a positive chemotactic agent.(GandH)Confocalmicroscopyof aKi67pos (G; arrow)CSCGFP (arrowheads) andaC
(I) Immunohistochemistry with antibody against SDF-1 (green; inset shows CM-s
(J and K) Quantification of CXCR4KOc-kitposCSCsGFP (J) and c-kitposCSCGFP in ra
CTRL. #p < 0.05 versus ISO 1 day.
All data are mean ± SD. See also Tables S2, S3, and S4 and Figure S5.c-kitposeCSCs Are Necessary and Sufficient for Myocyte
Regeneration and Functional Recovery after Severe
Diffuse Myocardial Damage
To test whether c-kitposeCSCs are necessary and/or sufficient
for myocardial anatomical and functional regeneration, 3 days
after ISO, we eliminated the proliferating eCSCs and their prog-
eny through administration of the antimitotic agent 5-flurouracil
(5-FU; 10 mg kg1). This regime (ISO+5-FU) ablated eCSC
expansion and new CM formation (Figures 5A–5C), resulting
in a severe cardiomyopathy (ISO+5-FU induced) (Figure 5D)
with a deficit and significant hypertrophy of the spared CMs,
as compared to animals treated with ISO alone (ISO+saline),
in which regeneration was normal (Figure S6). Although all
ISO+saline animals survived the acute myocardial insult and
fully recovered cardiac function, the ISO+5-FU animals devel-
oped heart failure (Figures 5D and S6) with increased mortality
(4 of 10 ISO+5-FU-treated animals versus 0 of 10 for the ISO+
saline animals) at 28 days. These effects were not due to 5-FU
toxicity because the same 5-FU regime administered to control
animals did not cause any cellular or functional cardiac or extra-
cardiac toxic effects, including in the bone marrow (Figure S6).
However, 5-FU would have targeted other replicating cells
together with activated eCSCs. Indeed, at 3 days after ISO
when 5-FU started to be administered, the eCSCs represented
only 17 ± 3% of total Ki67-positive myocardial cells, whereas
55 ± 4% were inflammatory cells (i.e. granulocytes and macro-
phages). A small fraction was cycling cardiac fibroblasts (9 ±
2%), smooth muscle (4 ± 1%), and endothelial (5 ± 2%) cells.
To evaluate the effect, if any, of ablating non-eCSCs on block-
ing the regenerative response and simultaneously to establish
a causal relationship between eCSC activation on one hand
andmyocardial regeneration and repair on the other, we injected
53 105 cloned CSCsGFP or the same number of GFPpos cardiac
fibroblasts (cFibro) into the tail vein of rats with ISO+5-FU cardio-
myopathy 28 days after ISO. Additionally, to address whether
the transplanted cells and their progeny are continuously
required to maintain cardiac cell homeostasis and functional
recovery, in a separate set of animals, we transplanted cells
from an eCSC clone expressing GFP together with the herpes
simplex virus thymidine kinase (CSCGFP/TK). Ganciclovir (GCV)
administration produces selective suicide of the transplanted
CSCGFP/TK and their progeny (Figure S7). As an additional con-
trol, saline was tail-vein injected into another group of animals.
See Figure 6A for the study design.
At 2months, the surviving rats with ISO+5-FU cardiomyopathy
that received either saline or cFibro were indistinguishable and
in overt heart failure with a dramatic deficit in c-kitposeCSCs, a
lack of CM regeneration, and increased CM death and hypertro-
phy (Figures 6B, 6D, and S7). In contrast, 95% of the animals
treated with CSCsGFP were alive at 2 months, showing efficient
homing and nesting of CSCsGFP into the damaged myocardium,
which had reconstituted the resident eCSC pool (90% cellSCGFP-derivedCM28daysafter ISOand tail-vein injection (H).Scale bar, 20mm.
pecific expression) in the ISO-injured myocardium. Scale bar, 20 mm.
ts treated with a SDF-1-neutralizing antibody (SDF-1Ab) (K). *p < 0.05 versus
Cell 154, 827–842, August 15, 2013 ª2013 Elsevier Inc. 835
Figure 5. Ablation of c-kitpos eCSCs Blocks Myocyte Regeneration
(A and B) Quantification of c-kitposeCSCs and Ki67pos new CM formation after ISO+5-FU treatment. *p < 0.01 versus CTRL and 5-FU.
(C) Confocal microscopy representative immunostaining of c-kit and Ki67 on ISO+5-FU-treated LV sections compared to 3 and 28 days after ISO. Scale bar,
30 mm.
(D) Echocardiographic LV function measurements following ISO+5-FU administration compared to ISO+saline. *p < 0.05 versus CTRL and 5-FU.
All data are mean ± SD. See also Figure S6.
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Figure 6. Restoration of the eCSC Pool through Exogenous c-kitpos eCSC Transplantation Normalizes Myocardial Tissue Composition
and Function
(A) Brief schematic of in vivo rat study design.
(B and C) Echocardiography and hemodynamic measurements after tail-vein injection of saline, cFibro, CSCsGFP, or CSCsGFP/TK in ISO+5-FU-treated rats and
after administration of GCV to CSCsGFP/TK animals. *p < 0.05 versus CTRL.
(D) Quantification of c-kitposeCSC and GFPposCMs. *p < 0.05 versus CTRL; xp < 0.05 versus groups at 2 months; #p < 0.05 versus groups at 3 months.
(E) Representative confocal microscopy of c-kitpos (white) CSCsGFP (green) in the myocardium of rats with ISO+5FU cardiomyopathy rescued by CSCGFP
injection.
(F) Flow cytometric analysis of c-kitposCSCsGFP isolated 2 months after tail vein injection.
(G and H) Confocal microscopy of c-kitposCSCsGFP-derived CMs in situ and following isolation at 3 months after tail-vein injection. Scale bar, 20 mm.
All data are mean ± SD. See also Figures S7 and S8 and Table S5.
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chimerism; Figures 6D, 6F, and S7). These CSCGFP chimeric
hearts had complete restoration of ventricular volumes and func-
tion (Figures 6B, 6C, and S7 and Table S5) with 8% GFPpos
CMs (Figure 6D), indicating that they are the progeny of the
transplanted cells. These data, in addition to highlighting the
homing and regenerative capacity of the CSCs, also point to
these cells as one of the cell targets of the in vivo direct reprog-
ramming protocols for myocardial regeneration using retroviral
vectors encoding CM-determining genes (Qian et al., 2012;
Song et al., 2012).
To rule out that cell fusion was the source of the new GFPpos
CMs in the CSCsGFP-transplanted animals, cloned male
CSCsGFP were injected into female rat recipients with ISO+5FU
cardiomyopathy as above. X and Y chromosomes were identi-
fied in GFPpos cells and their CM progeny. None of the GFPpos
cells had more than one X chromosome, ruling out cell fusion
as the source of the GFPpos CMs (Figure S7). Furthermore,
cloned c-kitposeCSCs from MerCreMer mice transduced with
red fluorescence protein were injected into RYP mice with
ISO+5FU cardiomyopathy and chased with tamoxifen before
sacrifice. We could not detect any red-labeled eCSC-derived
CMs expressing EYFP, which, if present, would identify cell
fusion (Figure S7).
Histological and functional results identical to the injection
of exogenous CSCsGFP were obtained in ISO+5FU-induced
cardiomyopathic animals by injection of GFPposTKposCSCs
(CSCsGFP/TK) (Figures 6B–6D and S7 and Table S5). At 56 days
(2 months), additional animals with ISO+5-FU cardiomyopathy
rescued by exogenous CSCsGFP or CSCsGFP/TK were treated
with either saline or GCV for 2 weeks and sacrificed at 84 days
(3 months). At this time point, CSCsGFP and CSCsGFP/TK rats
treated with saline showed a fully reconstituted eCSC pool
together with myocardial regeneration and repair (Figures 6D,
6G, and S7). Myocardial immunohistochemistry was corrobo-
rated at the single-cell level, quantifying isolated rod-shaped
GFPpos CMs by immunocytochemistry and FACS (Figures 6H
and S8). CSC-derived GFPpos CMs were still mostly mononucle-
ated but had a size comparable to pre-existing CMs, indicating
that the maturation of newly generated CMs is completed in
2 months (Figures 6G and S8). Furthermore, CSCGFP-derived
CMs expressed cardiac transcription factors and contractile
genes with mRNA levels comparable with normal adult CMs
(Figure S8).
GCV treatment did not cause any histological or functional
adverse effects to the rats in the ISO+5-FU+CSCGFP group.
In contrast, GCV treatment of ISO+5-FU+CSCsGFP/TK groupFigure 7. Reisolated CSCsGFP Retain Tissue-Specific Stem Cell Prope
(A–D) CSCGFP isolated from cell chimeric hearts produces single-cell-derived cl
CSCGFP. Scale bar, 100 mm.
(E and F) qRT-PCR transcript profile (E) and profile over passage number (F) of r
(G–J) Immunocytochemistry identifies reisolated CSCGFP cardiospheres (G), wh
(J; vWF) cells in vitro. Scale bar, 50 mm.
(K and L) LV functionmeasurements (K) and quantification of newGFPpos CMs (L) f
0.05 versus Sham and yp < 0.05 versus saline) (L, *p < 0.05 versus Distant).
(M–P) Confocal microscopy of new GFPpos CMs (cTnI; M and N), arteries (SMA; O
20 mm (N–P).
All data are mean ± SD. See also Figure S9.activated the programmed suicide of CSCsGFP/TK and their prog-
eny, which caused a dramatic reversal of all the recovered
cellular and functional parameters (Figures 6D and S7). At
3 months, the myocardium was devoid of CSCsGFP/TK and
of GFPpos CM progeny (Figure 6D), which was accompanied
by pathologic remodeling, ventricular chamber dilation, and
hemodynamic deterioration to levels of overt cardiac failure (Fig-
ure 6D and Table S5).
Finally, the reported ‘‘bystander effect’’ of GCV (Yoon et al.,
2010) was ruled out by several lines of evidence. First, GCV
at a concentration sufficient to kill the CSCsGFP/TK cultured
with adult rat ventricular CMs in a 10:1 ratio does not affect
survival of the latter (Figure S8). Second, early time points after
GCV administration showed death of only CSCsGFP/TK and
CSCsGFP/TK-derived CMs and not of the larger spared GFPneg
neighboring CMs (data not shown). Third, GCV-derived metabo-
lites effectively kill cycling cells, whereas noncycling terminally
differentiated cells are naturally resistant to it.
Transplanted CSCsGFP Reisolated after Having
Regenerated the Damaged Myocardium Retain
Tissue-Specific Stem Cell Properties
To test whether, after transplantation, some of the engrafted
GFPpos cells remain bona fide eCSCs, cells dissociated from
the hearts with ISO+5-FU cardiomyopathy rescued by CSCsGFP
were FACS sorted for c-kit and GFP. These c-kitposCSCsGFP
reisolated from the transplanted hearts exhibited a phenotype
indistinguishable from the parental c-kitposCSCGFP clone origi-
nally transplanted (Figure 7). They were clonogenic, self-renew-
ing, formed typical cardiospheres, and differentiated into CMs,
endothelial, and smooth-muscle cells in vitro (Figures 7A–7J).
A clone of the reisolated c-kitposCSCGFP, when transplanted
back into rats with ISO+5FU cardiomyopathy, proved indistin-
guishable from the primary parental clone in their efficiency to
replenish the depleted eCSC and CM-pool and reverse the
severe cardiac dysfunction (Figure S9). Furthermore, when these
reisolated cells were transplanted into rats with acutemyocardial
infarction, they repopulated the ischemic myocardium with new
GFPpos CMs and vascular cells, leading to improved LV function
(Figures 7K–7Q).
DISCUSSION
The results presented here demonstrate that c-kitposeCSCs
behave as true resident, endogenous stem cells, which are
necessary and sufficient for myocardial repair and cellularrties
ones (A–C) and cardiospheres (D) with similar efficiency to the clonal parental
eisolated CSCGFP.
ich differentiated into CMs (H; cTnI), smooth muscle (I; SMA), and endothelial
ollowing injection of reisolated clonal CSCGFP into the infarcted rat heart (K, *p <
), and capillaries (vWF; P) in the border/infarct area. Scale bar, 100 mm (M) and
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homeostasis. These results, however, do not rule out the partic-
ipation of other cardiac stem-cell-like populations (Oh et al.,
2003; Chong et al., 2011; Smart et al., 2011) or minor contribu-
tions by other cells (Senyo et al., 2013). Because the c-kit/cre
lentivirus strategy labeled approximately half of the c-kitpos
eCSCs in the LV (Figure 3), these results cannot determine
whether the fraction of newly generated EYFPneg CMs was not
labeled because of the lentivirus inefficiency in vivo or because
some of them are the progeny of c-kitneg stem and progenitor
cells. Nonetheless, the replacement of the eCSC cohort by
the progeny of a single CSC convincingly favors the first
alternative.
It is generally accepted that, in healthy adult tissue, most stem
cells are quiescent and if they cycle they do so very slowly,
providing just enough transient amplifying cells to maintain tis-
sue homeostasis (Orford and Scadden, 2008). In contrast, the
quiescent stem cells in response to injury are rapidly activated,
multiply, and differentiate to replace the cells lost. In the healthy
adult myocardium, >90% of the c-kitposeCSCs are quiescent
(G0) (Figure 1). In response to diffuse ISO injury, most eCSCs
enter the cell cycle, replicate, and commit to the myocardial
cell lineages (Figure 1), including CMs (Figure 3). Once the
ISO-induced cell loss and cardiac failure have been corrected
by the regenerated cells, the number of activated eCSCs
diminishes progressively with a concomitant increase of the
quiescent cohort (Figure 1). Thus, the return to myocardial
homeostasis is accompanied by the return of activated eCSCs
to their quiescent state. This roundtrip from dormancy to acti-
vation and back to quiescence has been suggested for other
self-renewing organs (Wilson et al., 2008). This toggling between
eCSC cycling states might just highlight the important role of
these cells in the homeostasis of a tissue essential for organismic
survival. Understanding the mechanisms by which cycling
eCSCs return to quiescence has clinical implications to exploit
the regenerative potential of these cells.
The efficiency of some adult stem cells, such as HSCs and
eCSCs, to specifically home to and nest into their tissue of
origin is dependent on tissue damage together with depletion
of the resident stem cells. This is so because the number
of tissue niches appears to be limited and nonexpandable
(Czechowicz et al., 2007). Here, we show that the injured
myocardium provides a milieu that supports the homing, nest-
ing, survival, and differentiation of the CSCs (Figure 4). How-
ever, if after injury the eCSCs are left in the tissue, despite
the very effective cardiac homing of the transplanted CSCGFP,
only a very small number succeed in long-term nesting in the
myocardium. This behavior contrasts with a host myocardium
that has been depleted of most eCSCs prior to transplantation
(Figures 5 and 6). Then the empty niches are very efficiently
occupied by the CSCsGFP transplanted through the systemic
circulation, which not only survive but differentiate into the
four main myocardial cell types and reconstitute the resident
eCSC pool (Figure 6). The sturdiness of the CSC homing,
engraftment, and regenerative properties after many passages
in culture and cloning (Figure 7) contrasts with the reported loss
of engraftment of ex-vivo-expanded HSCs (Guenechea et al.,
1999) and skeletal muscle satellite cells (Montarras et al.,
2005). Therefore, this robust homing of the eCSCs could be840 Cell 154, 827–842, August 15, 2013 ª2013 Elsevier Inc.exploited to replace the stem cell population of the myocar-
dium by noninvasive means, as clinically implemented now
for the bone marrow.
The HSCs are the best-understood adult stem cells and have
become the standard for most adult stem cell biology. Unfortu-
nately, solid tissues have serious experimental limitations over
the bone marrow, in which it is possible to transplant a single
genetically tagged HSC and follow its progeny in the host (Rossi
et al., 2008). That no such feat is possible in solid tissues has
hampered most attempts to define the role of tissue-specific
stem cells in the regenerative process. So far there is no report
of replacing the ablated stem cells with genetically tagged exog-
enous cells in solid tissues. Such replacement is required to
produce a chimeric tissue whose regeneration can be shown
to be dependent on the transplanted cells. In the myocardium,
the best approximation to the HSC paradigm is transplantation
of the progeny of a single cell. The high degree of cell chimerism
obtained by transplantation of cloned CSCsGFP and CSCTK/GFP
shows that the progeny of a single CSC can reconstitute the
5-FU ablated eCSC cohort and generate a cell chimeric heart
with new cardiomyocytes and vascular cells, thereby restoring
cardiac function. That the cellular and functional regeneration
of the ISO-damaged myocardium is due to the transplanted
CSCs is clearly shown by the rapid deterioration of cardiac
function when these cells and their progeny are selectively killed
by the GCV (Figure 6).
The data presented here support the conclusion that the
eCSCs are necessary and sufficient for anatomical and func-
tional regeneration of the adult mammalian myocardium.
EXPERIMENTAL PROCEDURES
Animals
Diffuse myocardial damage was induced by a single injection (s.c.) of ISO
to rats (5 mg kg1) or mice (200 mg kg1). To ablate cycling cells, including
eCSCs, after ISO-damage, 5-FU (Sigma) was administered (10 mg kg1)
for four cycles of 5 days each, starting at the third day post-ISO injection.
Mer-CreMer mice were kindly provided by Drs. Tammie Bishop and
Ludwig Thierfelder. ZEG and RYP mice were purchased at Jackson Labora-
tory. GCV was administered (i.p.) at the dose of 50 mg kg1 twice daily for
14 days.
Lenti c-kit/cre
The c-kit/cre construct was generated starting from a construct encoding the
EGFP gene under the c-kit promoter (Cairns et al., 2003) by replacing EGFP
with the CRE gene.
Statistical Analysis
Data are reported asmean ±SD. Significance was determined by ANOVA. The
Bonferroni post hoc method was used to locate the differences. Significance
was set at p < 0.05.
ACCESSION NUMBERS
The GEO accession number for the microarray data reported in this paper is
GSE49318.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, nine
figures, and seven tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.07.039.
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